About Us:
BridgeBio is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials, including Autosomal Dominant Hypocalcemia Type 1, achondroplasia and hypochondroplasia programs.
BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com
Address:
1800 Owens St, Suite C 1200
San Francisco, CA 94158
United States
Phone:
(650) 391-9740
Email:
Website:
Enter the MAP Spotlight Raffle